We are live on ! Find out more

920 hedge funds and large institutions have $14.5B invested in GSK in 2021 Q4 according to their latest regulatory filings, with 192 funds opening new positions, 322 increasing their positions, 247 reducing their positions, and 52 closing their positions.

New
Increased
Maintained
Reduced
Closed

269% more first-time investments, than exits

New positions opened: 192 | Existing positions closed: 52

168% more call options, than puts

Call options by funds: $624M | Put options by funds: $233M

46% more funds holding in top 10

Funds holding in top 10: 13 → 19 (+6)

30% more repeat investments, than reductions

Existing positions increased: 322 | Existing positions reduced: 247

20% more capital inflows, than outflows

Capital inflows: $1.1B | Capital outflows: $915M

16% more funds holding

Funds holding: 794 → 920 (+126)

0.17% more ownership

Funds ownership: 12.86% → 13.03% (+0.17%)

Holders
920
Holders Change
+126
Holders Change %
+15.87%
% of All Funds
14.1%
Holding in Top 10
19
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+46.15%
% of All Funds
0.29%
New
192
Increased
322
Reduced
247
Closed
52
Calls
$624M
Puts
$233M
Net Calls
+$391M
Net Calls Change
+$227M

GSK Hedge Fund Activity: Q4 2021 in Review

920 of the 6,524 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q4 2021, worth a combined $14.5B — up 17% from $12.4B a quarter earlier.

Buyers outnumbered sellers: 192 funds opened new GSK positions and 52 closed out — a net gain of 140 holders — while 322 added to existing stakes and 247 trimmed.

The largest buyer was Nomura Holdings, adding an estimated $175M. The largest seller was UBS Group, cutting an estimated $253M.

  • 920 institutional investors held GSK (GSK) as of Q4 2021, up from 794 in Q3 2021.
  • Funds reported $14.5B of GSK stock for Q4 2021, up 17% quarter-over-quarter.
  • 192 funds opened new GSK positions in Q4 2021 and 52 closed out, a net change of +140 holders.
  • The largest GSK buyer in Q4 2021 was Nomura Holdings, an estimated $175M added.
  • The largest GSK seller in Q4 2021 was UBS Group, an estimated $253M sold.

Based on aggregated 13F filings for Q4 2021.